Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study K Ihara, S Ohtani, N Watanabe, N Takahashi, N Miyazaki, K Ishizuchi, ... The Journal of Headache and Pain 24 (1), 23, 2023 | 30 | 2023 |
Mesolimbic dopamine release precedes actively sought aversive stimuli in mice Y Yawata, Y Shikano, J Ogasawara, K Makino, T Kashima, K Ihara, ... Nature communications 14 (1), 2433, 2023 | 14 | 2023 |
Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing K Ihara, S Ohtani, N Watanabe, N Takahashi, N Miyazaki, R Takemura, ... Journal of the Neurological Sciences 453, 120811, 2023 | 6 | 2023 |
The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study M Waliszewska-Prosół, DA Montisano, M Antolak, F Bighiani, ... The Journal of Headache and Pain 25 (1), 27, 2024 | 4 | 2024 |
A prediction model of qi stagnation: A prospective observational study referring to two existing models A Maeda-Minami, K Ihara, T Yoshino, Y Horiba, M Mimura, K Watanabe Computers in Biology and Medicine 146, 105619, 2022 | 3 | 2022 |
A reinforcement learning model with choice traces for a progressive ratio schedule K Ihara, Y Shikano, S Kato, S Yagishita, KF Tanaka, N Takata Frontiers in Behavioral Neuroscience 17, 1302842, 2024 | 2 | 2024 |
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review T Takizawa, K Ihara, S Uno, S Ohtani, N Watanabe, N Imai, J Nakahara, ... Expert Opinion on Drug Metabolism & Toxicology 19 (12), 951-967, 2023 | 2 | 2023 |
Posttraumatic headache is a distinct headache type from migraine K Ihara, TJ Schwedt Current opinion in neurology 37 (3), 264-270, 2024 | 1 | 2024 |
CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society T Takizawa, K Ihara, N Watanabe, R Takemura, N Takahashi, N Miyazaki, ... The Journal of Headache and Pain 25 (1), 39, 2024 | 1 | 2024 |
Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study S Ohtani, N Watanabe, K Ihara, N Takahashi, N Miyazaki, K Ishizuchi, ... BMC neurology 23 (1), 404, 2023 | 1 | 2023 |
頭痛研究の現状と展望 滝沢翼, 井原慶子 脳神経内科= Neurology/脳神経内科編集委員会 編 98 (3), 318-324, 2023 | 1 | 2023 |
日本のリアルワールドにおける CGRP 関連抗体薬の動向 大谷星也, 井原慶子, 堀里子, 中原仁, 滝沢翼 日本頭痛学会誌 49 (3), 578-583, 2023 | 1 | 2023 |
Are we closer to achieving precision medicine for migraine treatment? A narrative review K Ihara, F Casillo, A Dahshan, H Genç, A Jusupova, K Karbozova, W Lee, ... Cephalalgia 44 (9), 03331024241281518, 2024 | | 2024 |
Application of Artificial Intelligence in the Headache Field K Ihara, G Dumkrieger, P Zhang, T Takizawa, TJ Schwedt, CC Chiang Current pain and headache reports, 1-9, 2024 | | 2024 |
Potential benefits and possible risks of multitherapy CGRP-targeted in migraine. K Ihara, T Takizawa, N Watanabe, J Nakahara, P Martelletti Expert Opinion on Drug Metabolism & Toxicology, 2024 | | 2024 |
Potential benefits and possible risks of CGRP-targeted multitherapy in migraine K Ihara, T Takizawa, N Watanabe, J Nakahara, P Martelletti Expert Opinion on Drug Metabolism & Toxicology 20 (1-2), 1-4, 2024 | | 2024 |
Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan K Ihara, N Takahashi, S Ohtani, N Watanabe, K Ishizuchi, R Takemura, ... Internal Medicine, 4037-24, 2024 | | 2024 |
Response to letter:“Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule” by … K Ihara, S Ohtani, N Watanabe, N Takahashi, S Hori, J Nakahara, ... Journal of the Neurological Sciences 455, 2023 | | 2023 |
Comparison of responders and non-responders to CGRPmAb in patients with chronic migraine in Japan: a single-center retrospective observational study K Ihara, S Ohtani, N Watanabe, N Takahashi, N Miyazaki, K Ishizuchi, ... CEPHALALGIA 43 (1 supp), 226-227, 2023 | | 2023 |
Switching from galcanezumab to fremanezumab in migraine patients: a retrospective analysis (P7-12.011) T Takizawa, S Ohtani, N Watanabe, K Ihara, N Takahashi, N Miyazaki, ... Neurology 100 (17_supplement_2), 1802, 2023 | | 2023 |